

MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG

Cytos Biotechnology sells platform technology for the identification of monoclonal antibodies to Intercell

Schlieren (Zurich), Switzerland, May 6, 2010 – Cytos Biotechnology Ltd (SIX:CYTN) announced today that it has signed an agreement with Intercell (VSE:ICLL) to sell its platform technology for the identification of monoclonal antibodies. The technology is based on expression cloning of monoclonal antibodies from human B-cells and enables the identification of anti-infective antibodies to prevent and treat infectious diseases.

Under the agreed terms Intercell will pay EUR 15 million (corresponding to CHF 21.5 million) to Cytos. The technology, which is a specific application of Cytos' broader discovery platform DELphi will be transferred to Intercell, including promising pre-clinical anti-infective monoclonal antibody candidates discovered by Cytos. The key scientists, who have successfully developed the technology at Cytos, will be employed by Intercell.

The primary applications of the monoclonal antibody discovery platform are in the field of infectious diseases, an area which is outside of Cytos' core business of chronic disease vaccine development. Therefore, Cytos Biotechnology elected to monetize this non-core asset and use the proceeds of the transaction in its therapeutic vaccine programs.

Dr. Wolfgang Renner, CEO of Cytos Biotechnology commented the transaction: "Intercell is a leading anti-infective company and is ideally positioned through its Antigen Identification Program (AIP®) to capture the full value of our monoclonal antibody discovery platform. We are very glad that our innovative technology will enable Intercell to discover important new monoclonal antibodies for the treatment of infectious diseases."

Gerd Zettlmeissl, Chief Executive Officer of Intercell added "Cytos' outstanding antibody technology compliments our innovative R&D technology platform and enables pipeline progression within our existing portfolio."

Monoclonal antibodies form one of the fastest growing segments of the pharmaceutical industry. The global monoclonal antibodies market was valued at \$27.4 billion in 2008, indicating a Compound Annual Growth Rate (CAGR) of 30.8% between 2000 and 2008.¹

"Antibodies can be extremely effective for the prevention and treatment of infectious diseases. For example, the increasing rate of antibiotic resistance among certain types of nosocomial pathogens make it extremely difficult to control hospital acquired infectious diseases in critical situations. Anti-infective antibodies, well known in the medical arena before the advent of antibiotic treatments, have experienced a comeback and monoclonal antibody products are expected to contribute to the control of severe infections that otherwise might be untreatable in the future", explained Eszter Nagy, Senior Vice President Research at Intercell.

¹ <http://www.marketresearch.com/product/display.asp?productid=2515126>

About Cytos Biotechnology

Cytos Biotechnology Ltd is a public Swiss biotechnology company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products – the Immunodrugs™. Immunodrugs™ are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. Immunodrugs™ are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. Taking advantage of the high flexibility of its Immunodrug™ platform, Cytos Biotechnology has built a diversified pipeline of Immunodrug™ candidates in various disease areas, of which six are currently in clinical development. The Immunodrug™ candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health. Founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich, the Company is located in Schlieren (Zurich). Currently, the Company has 81 full-time employees. Cytos Biotechnology Ltd is listed on the SIX Swiss Exchange (SIX:CYTN).

About Intercell AG

Intercell AG is an innovative biotechnology company that develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs. Intercell's vaccine to prevent Japanese Encephalitis is the Company's first product on the market. The Company's technology platforms include an antigen-discovery system, adjuvants and a novel patch-based delivery system (Vaccine Patch, Vaccine Enhancement Patch). Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including GSK, Novartis, Merck & Co., Inc., sanofi-aventis, and Pfizer (formerly Wyeth). The Company's pipeline of investigational products includes a Travelers' Diarrhea Vaccine Patch (Phase III), a Pseudomonas vaccine candidate (Phase II), a vaccine to prevent Pandemic Influenza combining our Vaccine Enhancement Patch with an injected vaccine (Phase II), a vaccine program for S. aureus, which is being developed with Merck & Co., Inc. (Phase II/III), as well as a vaccine candidate for Pneumococcus (Phase I). In addition, further products focused on infectious diseases are in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol "ICLL" (U.S. level one ADR symbol "INRLY").

For further information please contact:

Wolfgang A. Renner, PhD
Chief Executive Officer
Cytos Biotechnology Ltd
Phone: +41 44 733 47 03
Fax: +41 44 733 47 04
e-Mail: wolfgang.renner@cytos.com
Website: www.cytos.com

This foregoing press release may contain forward-looking statements that include words or phrases such as "will", "are expected to", "are intended for", "are designed to" or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of Cytos Biotechnology Ltd.